Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan

Masayuki Hashiguchi, Jun Hakamata, Mikiko Shimizu, Junya Maruyama, Tsuyoshi Shiga, Mayumi Mochizuki

Research output: Contribution to journalArticle

Abstract

Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Materials and methods: Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Results: Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Conclusion: Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels.

Original languageEnglish
Pages (from-to)310-320
Number of pages11
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume56
Issue number7
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rhabdomyolysis
Japan
Databases
Angiotensin Receptor Antagonists
Bilirubin
Pharmaceutical Databases
Pharmaceutical Preparations
Glucosidases
Alcoholic Hepatitis
Drug Combinations
Aspartate Aminotransferases
Benzodiazepines
HDL Cholesterol
Alkaline Phosphatase
Case-Control Studies
Body Mass Index
Multivariate Analysis
Odds Ratio
Insulin

Keywords

  • HMG-CoA reductase inhibitor (statin)
  • Nested case-control study
  • Postmarketing surveillance
  • Rhabdomyolysis
  • Risk factor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan. / Hashiguchi, Masayuki; Hakamata, Jun; Shimizu, Mikiko; Maruyama, Junya; Shiga, Tsuyoshi; Mochizuki, Mayumi.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 56, No. 7, 01.01.2018, p. 310-320.

Research output: Contribution to journalArticle

@article{c635c1ead3b64383a2340c1b319b93c9,
title = "Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan",
abstract = "Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Materials and methods: Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Results: Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Conclusion: Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels.",
keywords = "HMG-CoA reductase inhibitor (statin), Nested case-control study, Postmarketing surveillance, Rhabdomyolysis, Risk factor",
author = "Masayuki Hashiguchi and Jun Hakamata and Mikiko Shimizu and Junya Maruyama and Tsuyoshi Shiga and Mayumi Mochizuki",
year = "2018",
month = "1",
day = "1",
doi = "10.5414/CP203237",
language = "English",
volume = "56",
pages = "310--320",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "7",

}

TY - JOUR

T1 - Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan

AU - Hashiguchi, Masayuki

AU - Hakamata, Jun

AU - Shimizu, Mikiko

AU - Maruyama, Junya

AU - Shiga, Tsuyoshi

AU - Mochizuki, Mayumi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Materials and methods: Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Results: Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Conclusion: Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels.

AB - Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Materials and methods: Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Results: Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Conclusion: Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels.

KW - HMG-CoA reductase inhibitor (statin)

KW - Nested case-control study

KW - Postmarketing surveillance

KW - Rhabdomyolysis

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=85052236091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052236091&partnerID=8YFLogxK

U2 - 10.5414/CP203237

DO - 10.5414/CP203237

M3 - Article

C2 - 29701171

AN - SCOPUS:85052236091

VL - 56

SP - 310

EP - 320

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 7

ER -